238 related articles for article (PubMed ID: 34550964)
21. Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report.
Koerber RM; Held SAE; Vonnahme M; Feldmann G; Wenzel J; Gütgemann I; Brossart P; Heine A
J Cancer Res Clin Oncol; 2022 Mar; 148(3):743-748. PubMed ID: 34529129
[TBL] [Abstract][Full Text] [Related]
22. Blastic Plasmacytoid Dendritic Cell Neoplasm With Central Nervous System Involvement: A Case Report.
Molina Castro D; Perilla Suárez O; Cuervo-Sierra J; Moreno A
Cureus; 2022 Apr; 14(4):e23888. PubMed ID: 35530883
[TBL] [Abstract][Full Text] [Related]
23. Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Wilson NR; Pemmaraju N
Expert Opin Pharmacother; 2022 Mar; 23(4):431-438. PubMed ID: 35060807
[TBL] [Abstract][Full Text] [Related]
24. Relapse of tagraxofusp treated blastic plasmacytoid dendritic cell neoplasm with loss of CD123 expression.
Gulati R; Abu-Salah A; Salous T; Nassiri M
J Hematop; 2022 Mar; 15(1):35-39. PubMed ID: 38358597
[TBL] [Abstract][Full Text] [Related]
25. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in an Elderly Female: A Rare Case.
Al-Alwan A; Khalid F; Vyas C; Sirpal V; Bader H
J Community Hosp Intern Med Perspect; 2023; 13(4):79-81. PubMed ID: 37868236
[TBL] [Abstract][Full Text] [Related]
26. Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm.
Tandon A; Zhang Y; Sokol L
Drugs Today (Barc); 2019 Dec; 55(12):735-742. PubMed ID: 31942876
[TBL] [Abstract][Full Text] [Related]
27. Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
Luskin MR; Lane AA
Haematologica; 2024 Jan; 109(1):44-52. PubMed ID: 36951152
[TBL] [Abstract][Full Text] [Related]
28. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
[TBL] [Abstract][Full Text] [Related]
29. Blastic plasmacytoid dendritic cell neoplasm with a history of cytopenia: A case report.
Yan M; Wang W; Cen X; Wang L; Sun Y; Wang B; Ou J; Nong L; Ren H; Zhu P; Wang M
Diagn Cytopathol; 2020 Nov; 48(11):1102-1106. PubMed ID: 32374950
[TBL] [Abstract][Full Text] [Related]
30. Unique presentation of blastic plasmacytoid dendritic cell neoplasm: a single-center experience and literature review.
Paluri R; Nabell L; Borak S; Peker D
Hematol Oncol; 2015 Dec; 33(4):206-11. PubMed ID: 24850172
[TBL] [Abstract][Full Text] [Related]
31. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark.
Taylor J; Haddadin M; Upadhyay VA; Grussie E; Mehta-Shah N; Brunner AM; Louissaint A; Lovitch SB; Dogan A; Fathi AT; Stone RM; Tallman MS; Rampal RK; Neuberg DS; Stevenson KE; Horwitz SM; Lane AA
Blood; 2019 Aug; 134(8):678-687. PubMed ID: 31243042
[TBL] [Abstract][Full Text] [Related]
32. A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm with Orbital Tumor as the Initial Symptom.
Li P; Pang N; Li M; Xie J; Wang Y
Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623681
[TBL] [Abstract][Full Text] [Related]
33. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
Lee SS; McCue D; Pemmaraju N
Expert Rev Anticancer Ther; 2020 Jul; 20(7):543-550. PubMed ID: 32460559
[TBL] [Abstract][Full Text] [Related]
34. Blastic plasmacytoid dendritic cell neoplasm of the breast: A case report and review of the literature.
Lee HJ; Park HM; Ki SY; Choi YD; Yun SJ; Lim HS
Medicine (Baltimore); 2021 May; 100(19):e25699. PubMed ID: 34106594
[TBL] [Abstract][Full Text] [Related]
35. Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature.
Albiol N; Novelli S; Mozos A; Pratcorona M; Martino R; Sierra J
J Med Case Rep; 2021 Jun; 15(1):326. PubMed ID: 34172079
[TBL] [Abstract][Full Text] [Related]
36. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy.
Riaz W; Zhang L; Horna P; Sokol L
Cancer Control; 2014 Oct; 21(4):279-89. PubMed ID: 25310209
[TBL] [Abstract][Full Text] [Related]
37. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023.
Pemmaraju N; Kantarjian H
Clin Adv Hematol Oncol; 2023 May; 21(5):257-264. PubMed ID: 37145496
[TBL] [Abstract][Full Text] [Related]
38. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.
Zhang X; Sun J; Yang M; Wang L; Jin J
Crit Rev Oncol Hematol; 2020 May; 149():102928. PubMed ID: 32234682
[TBL] [Abstract][Full Text] [Related]
39. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Economides MP; Rizzieri D; Pemmaraju N
Curr Hematol Malig Rep; 2019 Dec; 14(6):515-522. PubMed ID: 31853773
[TBL] [Abstract][Full Text] [Related]
40. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
Pemmaraju N; Kantarjian H; Sweet K; Wang E; Senapati J; Wilson NR; Konopleva M; Frankel AE; Gupta V; Mesa R; Ulrickson M; Gorak E; Bhatia S; Budak-Alpdogan T; Mason J; Garcia-Romero MT; Lopez-Santiago N; Cesarman-Maus G; Vachhani P; Lee S; Bhatt VR; Blum W; Walter RB; Bixby D; Gojo I; Duvic M; Rampal RK; de Lima M; Foran J; Fathi AT; Hall AC; Jacoby MA; Lancet J; Mannis G; Stein AS; Mims A; Rizzieri D; Olin R; Perl A; Schiller G; Shami P; Stone RM; Strickland S; Wieduwilt MJ; Daver N; Ravandi F; Vasu S; Guzman M; Roboz GJ; Khoury J; Qazilbash M; Aung PP; Cuglievan B; Madanat Y; Kharfan-Dabaja MA; Pawlowska A; Taylor J; Tallman M; Dhakal P; Lane AA
Blood; 2023 Feb; 141(6):567-578. PubMed ID: 36399715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
